PRRT2 and non-Hodgkin lymphoma: Using an FOS strategy, we designed and prepared a set of structurally diverse analogs and evaluated how variations in their structures influence their binding to PKC, their in vitro translocation of a PKC fusion protein, and their enhancement of CD22 antigen density in in vitro models of ALL and AIDS-related NHL.